Drug Trial Radar · NCT04321070
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Last checked: Nov 20, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
550
Actual
Start
Sep 9, 2019
Primary completion
Dec 14, 2019
Study completion Mar 6, 2020
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
Conditions
- Acne Vulgaris
Interventions
Clindamycin PhosphateDrug
A thin film of investigation product will be applied to the affected areas of the face once daily
Clindamycin Phosphate RLDDrug
A thin film of investigation product will be applied to the affected areas of the face once daily
PlacebosDrug
A thin film of investigation product will be applied to the affected areas of the face once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Demonstration of BioequivalenceTime frame: Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Catawba Research LLC
Charlotte, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.